Olema Oncology to Participate in Upcoming Investor Conferences
Olema Oncology (Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer, has announced its participation in three upcoming investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Olema Oncology (Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer, has announced its participation in three upcoming investor conferences. The company will attend the Jefferies London Healthcare Conference on November 20, 2024, at 1:30 p.m. GMT, the Evercore HealthCONx Conference on December 3, 2024, at 2:10 p.m. ET, and Citi's Global Healthcare Conference on December 3, 2024, at 3:15 p.m. ET. The events will feature various presentation formats including fireside chats and panel discussions. Live webcasts will be available on Olema's investor relations website and archived for at least 30 days.
Details
News Market Reaction – OLMA
The recorded move for OLMA in the trading session of this news was +3.81%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that its management team will participate in the following upcoming investor conferences:
Jefferies London Healthcare Conference
Date: Wednesday, November 20, 2024, at 1:30 p.m. GMT (8:30 a.m. ET)
Location: London, UK
Format: Fireside Chat
7th Annual Evercore HealthCONx Conference
Date: Tuesday, December 3, 2024, at 2:10 p.m. ET
Location: Loews Coral Gables Hotel in Coral Gables, FL
Format: Fireside Chat
Citi’s 2024 Global Healthcare Conference
Date: Tuesday, December 3, 2024, at 3:15 p.m. ET
Location: Intercontinental Miami Hotel in Miami, FL
Format: Panel Discussion
Live webcasts of the presentations and any accompanying materials will be available under the News & Events section of Olema’s investor relations website at ir.olema.com. The webcasts will be archived for at least 30 days.
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for women living with cancer. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally-available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), currently in a Phase 3 clinical trial called OPERA-01. In addition, Olema is developing a potent KAT6 inhibitor (OP-3136). Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit us at www.olema.com.
IR and Media Contact
Courtney O’Konek, Vice President, Corporate Communications
media@olema.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.